... of BMY today as I continue to reduce my holdings to diversify my stock... in the profits from the stock's impressive run the past ...+ months I'll replace the BMY with other blue chips that ... my first pick Still own BMY stock that is the basis for ... trim. Hope this helps the stock go higher for all my ...

It was sarcasm. My using the word prophetic obviously didnt translate. Typical Cordari, he was whining about BMY. The stock bottomed on 11/30, the exact day he was calling for low 40's. Cordari has not made a post since that day with the stock rallying 37%.

It was sarcasm. My using the word prophetic obviously didnt translate. Typical Cordari, he was whining about BMY. The stock bottomed on 11/30, the exact day he was calling for low 40's. Cordari has not made a post since that day with the stock rallying 37%.

BMY announced plans to buy CELG ... 3Q2017 earnings presentation cratered CELG stock. WELCOME TO THE CELGENE CORPORATION... certain purchasers of Celgene common stock and your rights with respect... entities who purchased the common stock of Celgene between April 27... your transactions in Celgene common stock during the Class Period). You...

BMY announced plans to buy CELG ... 3Q2017 earnings presentation cratered CELG stock. WELCOME TO THE CELGENE CORPORATION... certain purchasers of Celgene common stock and your rights with respect... entities who purchased the common stock of Celgene between April 27... your transactions in Celgene common stock during the Class Period). You...

... as binary in terms of stock implications, as we wouldremain positive...-like label for deucravacitinib). For BMY,we also expect commentary relating ... year. ... We continue to favor BMY shares, with our Buy rating ... has been unchanged. On Milvexian, BMY/JNJ have discussed they will ... at the end of February, BMY reiterated that with Abecma the ... We are Buy rated on BMY. Our 12-month price target ...

... as binary in terms of stock implications, as we wouldremain positive...-like label for deucravacitinib). For BMY,we also expect commentary relating ... year. ... We continue to favor BMY shares, with our Buy rating ... has been unchanged. On Milvexian, BMY/JNJ have discussed they will ... at the end of February, BMY reiterated that with Abecma the ... We are Buy rated on BMY. Our 12-month price target ...

... fairly insignificant amount in XOM, BMY, and VZ. These are the... dividend yields in March 2020. BMY is a former employer, and...’t per se buy that stock*, but again, the dividend on... match in the form of BMY stock, for which they were sued ...

... fairly insignificant amount in XOM, BMY, and VZ. These are the... dividend yields in March 2020. BMY is a former employer, and...’t per se buy that stock*, but again, the dividend on... match in the form of BMY stock, for which they were sued ...

Now that BMY's stock price has exceeded its 12 month analyst consensus PT estimate of $76.21 on Yahoo Finance, is BMY's stock presently overvalued and a sell ? The Nektar flop doesn't help matters. I prefer small cap biopharma that has 100-fold long-term upside potential, with many near-term positive catalysts. Best wishes to all

Now that BMY's stock price has exceeded its 12 month analyst consensus PT estimate of $76.21 on Yahoo Finance, is BMY's stock presently overvalued and a sell ? The Nektar flop doesn't help matters. I prefer small cap biopharma that has 100-fold long-term upside potential, with many near-term positive catalysts. Best wishes to all

BMY: Adam Lenkowsky, SVP and GM, ... there by recommendation and the stock has been amongst the most ...

BMY: Adam Lenkowsky, SVP and GM, ... there by recommendation and the stock has been amongst the most ...

You have to assume BMY is very interested in taking ... against Astra Zeneca and Glaxo. BMY can easily make strong market... target to the cancer tumors. BMY has been struggling with revenue... moving into CLVS and that stock went from $5, into the ...

You have to assume BMY is very interested in taking ... against Astra Zeneca and Glaxo. BMY can easily make strong market... target to the cancer tumors. BMY has been struggling with revenue... moving into CLVS and that stock went from $5, into the ...

...)-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc... of Turning Point Therapeutics’ common stock at a price of $76... of Turning Point Therapeutics’ common stock and the expiration or termination...

...)-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc... of Turning Point Therapeutics’ common stock at a price of $76... of Turning Point Therapeutics’ common stock and the expiration or termination...

.... BMY paid Nektar 1 billion upfront, bought 850 million in Nektar stock... a 40/40 split with BMY that would be worth over...

.... BMY paid Nektar 1 billion upfront, bought 850 million in Nektar stock... a 40/40 split with BMY that would be worth over...